已收盤 08-15 16:00:00 美东时间
-0.670
-1.98%
Piper Sandler analyst Mark Lear maintains Civitas Resources (NYSE:CIVI) with a Overweight and lowers the price target from $57 to $54.
08-14 22:09
Civitas Resources, Inc. (NYSE:CIVI) ("Civitas" or the "Company") announced today that Wouter van Kempen, the current Chair of the Civitas Board of Directors (the "Board") has been named Interim Chief Executive Officer,
08-07 05:07
Reinstating a capital return strategy of allocating 50% of free cash flow, after the base dividend, to share buybacks and 50% to debt reduction on an annual basis. The Company's Board increased its share repurchase
08-07 04:29
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Crescent Energy (NYSE:CRGY) is set to give its latest quarterly earnings report...
08-02 01:02
Northern Oil & Gas (NYSE:NOG) is set to give its latest quarterly earnings ...
07-31 02:01
NEW YORK, July 30, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Civitas Resources, Inc. (NYSE: CIVI) br...
07-30 22:27
Piper Sandler analyst Mark Lear maintains Civitas Resources (NYSE:CIVI) with a Overweight and raises the price target from $54 to $57.
07-17 20:57
One of the most persistent myths in investing is that markets are perfectly eff...
07-10 21:15
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners:维持再鼎医药(ZLAB)"跑赢大市"评级,目标价从73美元升至75美元</p> <p>• 美银证券:维持BioCryst Pharma(BCRX)"买入"评级,目标价从13美元升至15美元
07-02 09:54